Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value

$951.19−8.22 (-0.86%)

Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –

Regeneron Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Regeneron Pharmaceuticals's EV/EBITDA was 22.1× on Nov 11, 2026, against 18.9× a year earlier. Over the last 5 years it ranged from 6.5× to 29.3×, with a median of 16.7×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	22.1×	+3.5
2025	Dec 31, 2025	18.6×	+2.0
2024	Dec 31, 2024	16.7×	−3.2
2023	Dec 29, 2023	19.9×	+8.2
2022	Dec 30, 2022	11.7×	+3.1
2021	Dec 31, 2021	8.6×	−7.9
2020	Dec 31, 2020	16.5×	+0.1
2019	Dec 31, 2019	16.4×	+0.1
2018	Dec 31, 2018	16.3×	−4.5
2017	Dec 29, 2017	20.8×	−10.4
2016	Dec 30, 2016	31.2×	−16.0
2015	Dec 31, 2015	47.2×	−4.6
2014	Dec 31, 2014	51.8×	+8.4
2013	Dec 31, 2013	43.4×	−9.2
2012	Dec 31, 2012	52.7×	–

Where these numbers come from

Parsed from the XBRL in Regeneron Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing